Company intelligence / Profile preview

NeurOptics

Irvine, California, United States

Ownership: Private
Development stage: Other

Overview

NeurOptics’ NPi Pupillometer is a commercialized device used in neurological and critical care settings for objective pupillary assessment. Its utility for outcome prognostication in acute brain injuries has been confirmed in numerous studies, and its device is adopted in over 650 hospitals in the U.S. and featured in more than 120 clinical studies, showing quantitative prognostic value unaffected by intoxication status or several ICU drugs

Therapeutic areas: Neurology
Modalities: Device
Industry: Physiological Monitoring

Partnerships

Masimo (Investor)Southern Cross Venture Partners (Investor)

Beyond the preview

Go deeper on NeurOptics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeurOptics.

Explore the full profile